LifeArc, University College London, NHS Blood and Transplant, and Great Ormond Street Hospital are advancing a gene therapy programme for CTLA-4 insufficiency, a rare inherited immune disorder that can cause severe lifelong illness and reduced life expectancy.
The therapy uses CRISPR/Cas9 gene editing to correct a faulty gene in a patient’s own immune cells before those cells are returned to the body. The programme is expected to move through further development and manufacturing before a planned first human Phase I clinical trial in up to eight patients, aged between one and 65, currently expected to begin in 2028.
CTLA-4 insufficiency disrupts one of the immune system’s main control mechanisms. CTLA-4 normally helps prevent T cells from becoming overactive, and when that regulation fails, patients can develop bowel inflammation, blood cell abnormalities, recurrent infections, and other serious complications. Symptoms often appear in childhood, while current treatment options largely manage the condition rather than correcting its genetic cause.
Bone marrow transplant can offer a potential cure in some cases, but it carries significant risks and is not available or suitable for every patient. The new programme is designed to create a patient-specific therapy by editing the patient’s own cells, avoiding the need for a donor match and targeting the underlying genetic defect more directly.
NHSBT’s Clinical Biotechnology Centre in Bristol will manufacture the AAV6 viral vector used to deliver the corrected gene into the patient’s T cells. GOSH will manufacture the final cell therapy product and act as sponsor of the clinical trial, with GOSH, University College London Hospitals, and the Royal Free Hospital expected to serve as treatment sites.
Advanced therapy programmes depend on manufacturing discipline as much as laboratory science. Viral vector production, cell processing, release testing, chain of custody, sterility assurance, and clinical logistics all influence whether a therapy can move from pre-clinical work into human use. A similar convergence is visible in biomanufacturing partnerships that bring cell line development, analytics, process work, and GMP manufacturing closer together, reducing technical handovers between discovery, development, and production.
Rare disease programmes place particular pressure on that model because patient numbers are small while manufacturing requirements remain exacting. Each clinical product may involve bespoke handling, specialist operators, controlled environments, and tight coordination between hospitals, academic teams, and production centres. The commercial scale may be limited, but the technical demands are no less severe than in higher-volume therapies.
The programme also strengthens the UK’s position in translational cell and gene therapy infrastructure. The Innovation Hubs for Gene Therapies network was created to help promising academic work move closer to patient use by providing vector and manufacturing capability that individual research groups may not possess. That capability is increasingly important as more advanced therapy candidates emerge from universities and hospitals with strong biology but limited industrial production routes.
Early pre-clinical studies have shown corrected cells demonstrating improved control of immune activity. The next phase will test whether the process can be developed, manufactured, and controlled in a form suitable for first human use, with the clinical programme designed to establish safety, feasibility, and early evidence of benefit.
If the approach progresses successfully, it could offer a longer-lasting treatment option for CTLA-4 insufficiency and provide a template for other rare immune disorders where gene correction in a patient’s own cells may be applicable. The immediate test is still manufacturing readiness: producing corrected cells consistently, safely, and within a hospital-linked advanced therapy workflow that can withstand clinical and regulatory scrutiny.
